Corbus Pharmaceuticals Holdings Business Summary

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements, research collaborations, and milestone payments rather than commercial product sales. The company operates through two primary business segments: Precision Oncology, which focuses on next-generation antibody-drug conjugates (ADCs) like CRB-701 and monoclonal antibodies like CRB-601, and Metabolic Diseases, centered on its peripherally restricted CB1 receptor inverse agonist, CRB-913, for the treatment of obesity. Corbus positions itself as a high-potential small-cap developer of "best-in-class" therapeutic candidates, competing directly with industry peers such as Viking Therapeutics in the obesity space, Pfizer (via Seagen) in the Nectin-4 ADC market, and Vanda Pharmaceuticals in the broader specialty drug landscape. The company is led by Co-founder and CEO Yuval Cohen, Ph.D., who previously served as President of Celsus Therapeutics and holds a doctorate from the Curie Institute of Cancer Research. The executive leadership team includes Chief Financial Officer Sean Moran, a veteran with over 25 years of experience in biotech finance and multiple successful IPOs, and Chief Operating Officer Ian Hodgson, Ph.D., who was appointed in March 2025 to oversee global drug development and operations. Clinical strategy is directed by Chief Medical Officer Dominic Smethurst, formerly of Bicycle Therapeutics, while the board is chaired by Rachelle Jacques, a seasoned executive with a track record at Akari Therapeutics and Enzyvant. Corbus is backed by prominent institutional investors, including OrbiMed Advisors, Cormorant Asset Management, and BlackRock, reflecting strong institutional confidence in its diversified clinical pipeline.